| 1.27 -0.08 (-5.93%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.73 | 1-year : | 1.92 |
| Resists | First : | 1.48 | Second : | 1.64 |
| Pivot price | 1.33 |
|||
| Supports | First : | 1.21 | Second : | 1 |
| MAs | MA(5) : | 1.36 |
MA(20) : | 1.34 |
| MA(100) : | 1.56 |
MA(250) : | 2.52 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 27.2 |
D(3) : | 34.8 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 7.13 | Low : | 1.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BRTX ] has closed above bottom band by 14.5%. Bollinger Bands are 67.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.36 - 1.37 | 1.37 - 1.38 |
| Low: | 1.23 - 1.24 | 1.24 - 1.25 |
| Close: | 1.26 - 1.27 | 1.27 - 1.28 |
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Tue, 16 Apr 2024
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment - GlobeNewswire
Mon, 08 Apr 2024
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 ... - Yahoo Finance
Wed, 03 Apr 2024
BioRestorative Therapies Full Year 2023 Earnings: Beats Expectations - Simply Wall St
Tue, 02 Apr 2024
BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q4 2023 - InvestorPlace
Mon, 01 Apr 2024
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K - Yahoo Finance
Mon, 11 Mar 2024
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 5.5e+006 (%) |
| Held by Institutions | 18.7 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.506e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -16 % |
| Return on Assets (ttm) | 687.4 % |
| Return on Equity (ttm) | -65.5 % |
| Qtrly Rev. Growth | 145800 % |
| Gross Profit (p.s.) | 6.83 |
| Sales Per Share | -1.71 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.75 |
| Price to Cash Flow | 31.97 |
| Dividend | 0 |
| Forward Dividend | 40500 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|